What Regimen Should be Used when Considering the Use of Adjuvant Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)?

Chemotherapy in the adjuvant setting is given together with another treatment (like surgery) to increase its effectiveness.

Patients with stage 2 NSCLC with tumours that have been completely removed by surgery should be offered 3-4 cycles of adjuvant cisplatin-based chemotherapy.

Performance status is an attempt to quantify cancer patients general well being. Patients who have a good performance status of 1 or 2 and stage 3 non-small cell lung cancer with tumours that have been completely removed by surgery should be offered adjuvant cisplatin-based chemotherapy. Cisplatin is a drug that interferes with DNA replication and hence cancer cell growth.